figshare
Browse
Back

Figure 4 from Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4

Download (1.9 MB)
Version 2 2025-03-28, 22:23
Version 1 2024-08-14, 10:08
figure
posted on 2025-03-28, 22:23 authored by Makito Mizunuma, Christophe E. Redon, Liton Kumar Saha, Andy D. Tran, Anjali Dhall, Robin Sebastian, Daiki Taniyama, Michael J. Kruhlak, William C. Reinhold, Naoko Takebe, Yves Pommier

Role of TRPM4 in the action of Acetalax. A, Scatter plot demonstrating the correlation between Acetalax activity versus TRPM4 expression in the TNBC cell lines of the GDSC-MGH-Sanger database used in the present study (Supplementary Fig. S4 for the overall dataset with all cancer tissue types). The x-axis shows Acetalax activity. The y-axis shows the TRPM4 transcript level measured by RNA-seq (log2). Both were visualized using CellMinerCDB. Each point is a TNBC cell line. The red line is the regression line. The Acetalax-sensitive cell lines are highlighted in red, and the resistant cell lines in blue. B, Western blots of TRPM4 levels in the five TNBC cell lines. GADPH was used as the loading control. C, Western blot of TRPM4 protein expression in MDA-MB468 and BT549 parental and TRPM4-KO cells. D, Acetalax cell viability assay in parental, TRPM4-KO, and CE cells. Cells were treated with Acetalax for 72 hours. Cell viability was determined using CellTiter-Glo 2. Experiments were performed in triplicate (n = 3). E, Western blot of TRPM4 expression in MDA-MB468 and BT549 parental and Acetalax-resistant (CE) cells. GADPH was used as the loading control. F, Representative microscopy images of parental MDA-MB468 cells and their resistant (CE) and TRPM4-KO counterparts. Cells were stained in blue with DAPI (binds DNA) and green with phalloidin (stains actin). Control, without Acetalax treatment. Scale bars, 50 μm. Cells were treated with Acetalax at 10 μmol/L for 30 minutes. Control, no drug. TRPM4 was degraded in the Acetalax-sensitive MDA-MB468 cells following Acetalax treatment for 4 hours. G, Quantification of repeated experiments as in F. Each cell and each nucleus are indicated by a dot. Numbers indicate the number of cells and nuclei analyzed.

History

ARTICLE ABSTRACT

Triple-negative breast cancer (TNBC) is clinically aggressive and relatively unresponsive to current therapies. Therefore, the development of new anticancer agents is needed to satisfy clinical needs. Oxyphenisatin acetate (Acetalax), which had been used as a laxative, has recently been reported to have anticancer activity in murine models. In this study, we demonstrate that Acetalax and its diphenolic laxative structural analogue bisacodyl (Dulcolax) exhibit potent antiproliferative activity in TNBC cell lines and cause oncosis, a nonapoptotic cell death characterized by cellular and nuclear swelling and cell membrane blebbing, leading to mitochondrial dysfunction, ATP depletion, and enhanced immune and inflammatory responses. Mechanistically, we provide evidence that transient receptor potential melastatin member 4 (TRPM4) is poisoned by Acetalax and bisacodyl in MDA-MB468, BT549, and HS578T TNBC cells. MDA-MB231 and MDA-MB436 TNBC cells without endogenous TRPM4 expression as well as TRPM4-knockout TNBC cells were found to be Acetalax- and bisacodyl-resistant. Conversely, ectopic expression of TRPM4 sensitized MDA-MB231 and MDA-MB436 cells to Acetalax. TRPM4 was also lost in cells with acquired Acetalax resistance. Moreover, TRPM4 is rapidly degraded by the ubiquitin–proteasome system upon acute exposure to Acetalax and bisacodyl. Together, these results demonstrate that TRPM4 is a previously unknown target of Acetalax and bisacodyl and that TRPM4 expression in cancer cells is a predictor of Acetalax and bisacodyl efficacy and could be used for the clinical development of these drugs as anticancer agents. Acetalax and bisacodyl kill cancer cells by causing oncosis following poisoning of the plasma membrane sodium transporter TRPM4 and represent a new therapeutic approach for TNBC.

Usage metrics

    Cancer Research Communications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC